Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Apellis

Biogen Conference: Lupus, Kidney Programs Take Center Stage in Immunology Push

Biogen (NASDAQ:BIIB) is continuing to position immunology as a larger part of its strategy, with late-stage lupus and kidney disease programs expected to shape the company’s next phase of growth, Adam Meyers, head of the company’s immunology and new disease areas franchise, said at Bank of America’s

Apellis Pharma Skyrockets on Biogen Deal. Is It Too Late to Chase APLS Stock?

Apellis Pharma Skyrockets on Biogen Deal. Is It Too Late to Chase APLS Stock?

Apellis Pharma stock more than doubled as Biogen announced a $5.6 billion acquisition. But for investors looking to jump into APLS shares now, the ship has already sailed.

This Undervalued Biotech Might Have Just Proven Its Star Drug's Staying Power

This Undervalued Biotech Might Have Just Proven Its Star Drug's Staying Power

On Wednesday, Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) announced data from a post hoc analysis of the GALE extension study following five years of continuous treatment with Syfovre (pegcetacoplan injection) for geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

FDA Approval For Empaveli Marks Key Milestone In Apellis' Rare Disease Portfolio

The U.S. Food and Drug Administration approved on Monday Apellis Pharmaceuticals, Inc.’s (NASDAQ:APLS) Empaveli (pegcetacoplan) as the first treatment for C3 glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) in patients 12 years of age and older, to reduce proteinuria.

Apellis Pharmaceuticals Reports Q2 Earnings Beat, Investigates Retinal Vasculitis Events

Apellis Pharmaceuticals beats Q2 earnings estimates with strong sales of SYFOVRE, but faces investigation into retinal vasculitis events

Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know

Editor's note: This story has been corrected to reflect that the FDA deferred action on Amicus Therapeutics' Biologics License Application.

Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary

The European Commission (EC) has granted conditional marketing authorization (CMA) to BioMarin Pharmaceutical’s (NASDAQ:BMRN) lead asset ROCTAVIAN (valoctocogene roxaparvovec) gene therapy for the treatment of severe hemophilia A (congenital Factor VIII deficiency) in adult patients. BioMarin shares traded as high as 2.28 percent, in a range of $91.39 to $93.68…

inkl

Read news from The Economist, FT, and more,
with one subscription

Why Apellis Pharmaceuticals Stock Is Falling After Hours

Why Apellis Pharmaceuticals Stock Is Falling After Hours

Apellis Pharmaceuticals Inc (NASDAQ: APLS) shares are trading lower in Wednesday's after-hours session after the company announced a proposed public offering of $300 million of its common stock.

Here's Why Apellis Pharmaceuticals Shares Are Rising

Here's Why Apellis Pharmaceuticals Shares Are Rising

Apellis Pharmaceuticals Inc (NASDAQ: APLS) shares are trading higher by 8.6% at $43.49 after the company announced Pegcetacoplan showed continuous and clinically meaningful effects at month 18 in Phase 3 Derby and Oaks studies for geographic atrophy.

1

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

European Commission

Bank of America

Food and Drug Administration

US Food and Drug Administration

Apellis Pharmaceuticals

Biomarin Pharmaceutical

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Macular Degeneration

Places

389,409 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play